MEI Pharma Investors: Company Investigated by the Portnoy Law Firm


Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MEI Pharma, Inc. (NASDAQ: MEIP) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. MEI Pharma investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On May 13, 2022, after market hours, MEI Pharma announced restatements of its financial statements for certain quarters for 2020 and 2021. In part, MEI Pharma stated, "[R]evenue was overstated in some quarters and understated in other quarters in the Company's financial statements during 2020 and 2021. The Company will therefore restate its previously filed annual and quarterly financial statements for periods from June 30, 2020 forward."

On this news, MEI Pharma share prices fell $0.0242, or 4.6%, to open at $0.4958 per share on May 16, 2022, damaging investors.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising